<![CDATA[EUSA Pharma 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=31226>Sat, 02 May 2026 20:37:14 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome]]>https://www.newswire.co.kr/newsRead.php?no=907335Fri, 03 Jul 2020 14:00:00 +0900<![CDATA[EUSA 파마, 코비드 19와 관련된 급성호흡곤란증후군 입원환자들에 대해 FDA로부터 실툭시맙 3상 임상시험 승인받아]]>https://www.newswire.co.kr/newsRead.php?no=907337Fri, 03 Jul 2020 14:00:00 +0900<![CDATA[EUSA파마와 이탈리아의 파파 지오바니 23 병원, COVID-19 환자를 실툭시맙으로 치료한 SISCO 연구의 중간 분석 데이터 발표]]>https://www.newswire.co.kr/newsRead.php?no=903305Thu, 02 Apr 2020 14:16:08 +0900<![CDATA[EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-Treated COVID-19 Patients from the SISCO Study]]>https://www.newswire.co.kr/newsRead.php?no=903301Thu, 02 Apr 2020 14:11:48 +0900<![CDATA[EUSA 파마와 이탈리아 베르가모 소재 파파 지오바니 23 병원, 코로나19 환자들 중 심각한 호흡기 합병증을 일으킨 환자들 대상 실툭시맙 환자-대조군 관찰 연구 착수했다고 발표]]>https://www.newswire.co.kr/newsRead.php?no=902711Thu, 19 Mar 2020 11:48:57 +0900<![CDATA[EUSA Pharma and the Papa Giovanni XXIII Hospital, Bergamo, Italy Announce Initiation of an Observational Case-control Study of Siltuximab in Patients with COVID-19 who have Developed Serious Respiratory Complications]]>https://www.newswire.co.kr/newsRead.php?no=902707Thu, 19 Mar 2020 11:40:52 +0900<![CDATA[New ESMO Guidelines Include FOTIVDA®▼(tivozanib) Recommendation for Patients with Advanced Renal Cell Carcinoma]]>https://www.newswire.co.kr/newsRead.php?no=884666Mon, 11 Mar 2019 10:10:00 +0900<![CDATA[Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA®▼ (Tivozanib) for Patients with Advanced Renal Cell Carcinoma]]>https://www.newswire.co.kr/newsRead.php?no=877522Mon, 22 Oct 2018 18:00:00 +0900<![CDATA[EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, QARZIBA®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma]]>https://www.newswire.co.kr/newsRead.php?no=872329Thu, 12 Jul 2018 16:15:00 +0900<![CDATA[EUSA 파마: NICE, 고위험군 신경모세포종 어린이 환자 치료에 표적 암 면역치료제 QARZIBA®▼ 승인]]>https://www.newswire.co.kr/newsRead.php?no=872330Thu, 12 Jul 2018 16:15:00 +0900